These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

707 related items for PubMed ID: 29069393

  • 1. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X, Ominsky MS, Villasenor KS, Niu QT, Asuncion FJ, Xia X, Grisanti M, Wronski TJ, Simonet WS, Ke HZ.
    Endocrinology; 2018 Jan 01; 159(1):260-271. PubMed ID: 29069393
    [Abstract] [Full Text] [Related]

  • 2. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
    Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ.
    Endocrinology; 2014 Dec 01; 155(12):4785-97. PubMed ID: 25259718
    [Abstract] [Full Text] [Related]

  • 3. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
    Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.
    Endocrinology; 2011 Sep 01; 152(9):3312-22. PubMed ID: 21733832
    [Abstract] [Full Text] [Related]

  • 4. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M, Dwyer D, Niu QT, Villasenor KS, Kurimoto P, Grisanti M, Han CY, Liu M, Li X, Ominsky MS, Ke HZ, Kostenuik PJ.
    Bone; 2014 Oct 01; 67():305-13. PubMed ID: 25093263
    [Abstract] [Full Text] [Related]

  • 5. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C.
    J Bone Miner Res; 2009 Apr 01; 24(4):578-88. PubMed ID: 19049336
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.
    Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.
    J Bone Miner Res; 2010 Dec 01; 25(12):2647-56. PubMed ID: 20641040
    [Abstract] [Full Text] [Related]

  • 7. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
    Ominsky MS, Brown DL, Van G, Cordover D, Pacheco E, Frazier E, Cherepow L, Higgins-Garn M, Aguirre JI, Wronski TJ, Stolina M, Zhou L, Pyrah I, Boyce RW.
    Bone; 2015 Dec 01; 81():380-391. PubMed ID: 26261096
    [Abstract] [Full Text] [Related]

  • 8. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
    Tian X, Jee WS, Li X, Paszty C, Ke HZ.
    Bone; 2011 Feb 01; 48(2):197-201. PubMed ID: 20850580
    [Abstract] [Full Text] [Related]

  • 9. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.
    Ominsky MS, Niu QT, Li C, Li X, Ke HZ.
    J Bone Miner Res; 2014 Jun 01; 29(6):1424-30. PubMed ID: 24967455
    [Abstract] [Full Text] [Related]

  • 10. The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.
    Wu J, Cai XH, Qin XX, Liu YX.
    Z Gerontol Geriatr; 2018 Jul 01; 51(5):550-556. PubMed ID: 28364259
    [Abstract] [Full Text] [Related]

  • 11. Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.
    Ma YL, Hamang M, Lucchesi J, Bivi N, Zeng Q, Adrian MD, Raines SE, Li J, Kuhstoss SA, Obungu V, Bryant HU, Krishnan V.
    Bone; 2017 Apr 01; 97():20-28. PubMed ID: 27939957
    [Abstract] [Full Text] [Related]

  • 12. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.
    Zhang D, Hu M, Chu T, Lin L, Wang J, Li X, Ke HZ, Qin YX.
    Bone; 2016 Jun 01; 87():161-8. PubMed ID: 26868528
    [Abstract] [Full Text] [Related]

  • 13. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption.
    Chandler H, Lanske B, Varela A, Guillot M, Boyer M, Brown J, Pierce A, Ominsky M, Mitlak B, Baron R, Kostenuik P, Hattersley G.
    Bone; 2019 Mar 01; 120():148-155. PubMed ID: 30343166
    [Abstract] [Full Text] [Related]

  • 14. Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis.
    Virdi AS, Irish J, Sena K, Liu M, Ke HZ, McNulty MA, Sumner DR.
    J Bone Joint Surg Am; 2015 Jan 21; 97(2):133-40. PubMed ID: 25609440
    [Abstract] [Full Text] [Related]

  • 15. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
    Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C.
    J Bone Miner Res; 2010 May 21; 25(5):948-59. PubMed ID: 20200929
    [Abstract] [Full Text] [Related]

  • 16. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
    Achiou Z, Toumi H, Touvier J, Boudenot A, Uzbekov R, Ominsky MS, Pallu S, Lespessailles E.
    Bone; 2015 Dec 21; 81():691-701. PubMed ID: 26409255
    [Abstract] [Full Text] [Related]

  • 17. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis.
    Chen H, Xu X, Liu M, Zhang W, Ke HZ, Qin A, Tang T, Lu E.
    Bone; 2015 Jul 21; 76():141-8. PubMed ID: 25868799
    [Abstract] [Full Text] [Related]

  • 18. Effects of sclerostin antibodies in animal models of osteoporosis.
    Ominsky MS, Boyce RW, Li X, Ke HZ.
    Bone; 2017 Mar 21; 96():63-75. PubMed ID: 27789417
    [Abstract] [Full Text] [Related]

  • 19. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis.
    Besschetnova T, Brooks DJ, Hu D, Nagano K, Nustad J, Ominsky M, Mitlak B, Hattersley G, Bouxsein ML, Baron R, Lanske B.
    Bone; 2019 Jul 21; 124():148-157. PubMed ID: 31051317
    [Abstract] [Full Text] [Related]

  • 20. Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats.
    Liu Y, Rui Y, Cheng TY, Huang S, Xu L, Meng F, Lee WY, Zhang T, Li N, Li C, Ke H, Li G.
    Calcif Tissue Int; 2016 Mar 21; 98(3):263-74. PubMed ID: 26603303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.